ARCHIVES

NCAB working Group Is Not Subject To Open Meetings Law, NCI Official Says

This article is from The Cancer Letter archive.

Vol. 20 No. 47 | December 9, 1994

Download PDF Visit The Full Archive

Related Articles

Genentech Reps Not Welcome: Hospitals Urge Drug Maker to Reverse Policy On Supplying Avastin, Rituxan, & Herceptin

October 17, 2014

Kimes Calls Headline On DRG ‘Exaggerated Negativity’ In Letter

April 5, 1991

FDA Committee nixes Combination Guidelines, Okays New NDA Policy

January 21, 1977

Bioassay Backlog To Be Cleared Up In Year: Squire

November 26, 1976

Lilly Begins Phase III Trial Of Alimta In Extensive SCLC

October 27, 2006

NCI Cooperative Group Clinical Trials Approved

May 29, 2009